drug

Fluvoxamine

fluvoxamine
MeSH D016666
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Sha'ar Menashe Mental Health Center
3 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

3
Pharmacovigilance in Gerontopsychiatric Patients
NCT02374567Phase 3Terminated
Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients
NCT01832285—Unknown
Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function
NCT00645580—Unknown

KOLs & investigators

3
Helge Frieling, Prof., MDKOL score 5
Henry Silver, PhD
Silver Henry, Professor

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Sha'ar Menashe Mental Health Center
company
trial
Pharmacovigilance in Gerontopsychiatric Patients
PHASE3
trial
Effect of Fluvoxamine on Cognition, Behavior, Symptoms and mRNA and Protein Expression in Schizophrenia Patients
NA
trial
Genetic Expression in Schizophrenics Treated With SSRI Augmentation: Relationship to Clinical and Cognitive Function
NA
trial
indication
Schizophrenia
indication
Depression
indication
Psychosomatic Disorders
indication
SCHIZOPHRENIA 1 (Disorder)
indication
KOL
Helge Frieling, Prof., MD
KOL score 5
person
Henry Silver, PhD
KOL score —
person
Silver Henry, Professor
KOL score —
person